BIOVECTRA Named One of Canada’s Top Employers Again in 2023

 

Charlottetown, P.E.I. (November 22, 2021) – BIOVECTRA was selected as one of Canada’s Top 100 Employers for a second consecutive year and is considered amongst the country’s leading workplaces.

BIOVECTRA is a fast growing, forward-thinking contract development, and manufacturing organization (CDMO) solving complex challenges to improve patient care for some of the world’s top pharmaceutical companies.

The company has a long-standing tradition of nurturing talent from its start-up days employing a dozen employees through to today as a diverse workplace with more than 600 employees in both Prince Edward Island and Nova Scotia.

“We are deeply humbled to be among the distinguished list of Canada’s Top 100 Employers two years in a row,” says Oliver Technow, CEO, BIOVECTRA.  “Today we celebrate, but most importantly, we recognize that this comes with the obligation to keep it up and to continue our journey with and for our amazing team in Windsor, NS and Charlottetown, PEI.”

In an era of tight competition for talent, BIOVECTRA stands out by demonstrating superior performance in a combination of areas such as: training and skills development; health/ family benefits; financial benefits; and employee engagement and performance.

“We are extremely proud of this designation because we continuously strive to be the best workplace that we can be,” explains Lester Wood, VP of People and Corporate Culture.  “There are stringent criteria that we are assessed against each year and what we offer as an employer is further compared to other similar organizations.”

As an employer BIOVECTRA is committed to supporting causes in the community that employees care about, embracing a learning and development culture, and creating more flexible health and family benefits to reflect employees’ diverse realities.

Helpful Links
www.biovectra.com
https://reviews.canadastop100.com/top-employer-biovectra

About BIOVECTRA
We are a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, small molecules, bioreagents, and pDNA and MRNA manufacturing.  Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, 600 employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.

About the 2023 Competition
Now in its 23rd annual edition, Canada’s Top 100 Employers is an editorial competition that recognizes employers with exceptional human resources programs and forward-thinking workplace policies. Editors at Mediacorp grade employers on eight criteria, which have remained consistent since the project’s inception: (1) Physical Workplace; (2) Work Atmosphere & Social; (3) Health, Financial & Family Benefits; (4) Vacation & Time Off; (5) Employee Communications; (6) Performance Management; (7) Training & Skills Development; and (8) Community Involvement. The editors publish detailed ‘reasons for selection’ for these criteria, providing transparency in the selection of winners and a catalogue of best practices for employers and job-seekers.

– 30 –

Media Contact
Bobbi Jo Walker
Director, Corporate Communication
BIOVECTRA
(902) 218-7649
[email protected]

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors